ACTO launches role-based AI SuperAgents for Life Sciences

ACTO has launched AI SuperAgents for Life Sciences field teams, describing the product as the first role-based AI agent for sales, medical and market access staff.

Based in Toronto and New York, ACTO says the system is organised around job roles rather than individual tasks and is aimed at customer-facing teams in the Life Sciences sector.

The company is targeting a part of the pharmaceutical and biotech market where artificial intelligence has been widely adopted in areas such as drug discovery, but has proved harder to use in day-to-day commercial and medical field work. Many existing tools are tied to isolated workflows or separate systems, limiting their usefulness for staff who need information from multiple sources while working under compliance rules.

The product is being positioned as a set of AI agents configured for specific roles across sales, medical, marketing, learning and development, patient services and market access. According to ACTO, the agents can work across internal systems and are designed to reflect job descriptions and working patterns for each role.

How it works

The product is built on four main elements: context, connection, control and change management. In practice, that means the agents draw on information about a user's role and working habits, connect with enterprise systems and other agents, and operate with audit trails and human oversight.

ACTO says the system is intended to support individuals rather than replace them. It also argues that role-specific design should make adoption easier by making the tool's purpose clearer to staff.

Parth Khanna, ACTO's chief executive officer, linked the launch to broader changes in how artificial intelligence is being used in healthcare and pharmaceuticals.

"We're at a pivotal moment in technological innovation," said Parth Khanna, Chief Executive Officer, ACTO. "AI is already transforming drug discovery-cutting years from development timelines and accelerating the delivery of new therapies to market. Our goal is to bring that same velocity to the post-approval phase, equipping customer-facing teams with role-based SuperAgents that automate workflows and free up more time to engage with HCPs-ultimately helping get therapies to the patients waiting in need. Having spent the last decade helping organizations build field excellence through training, coaching, and practice, this is a natural evolution for ACTO-uniting human intelligence with empathetic AI to define the future of work."

ACTO describes the product as "empathetic AI", saying the agents are designed to understand both the user's formal role and how that individual works. It says this should allow the system to provide information and suggested actions in real time while staying within internal governance structures.

Early use

One early user is Currax Pharmaceuticals, which is deploying the system across its commercial field organisation, including sales representatives and first-line managers.

Lisa Dreher, Director, National Sales Training at Currax Pharmaceuticals, said the company had used the tool to reduce time spent searching for information across different platforms.

"With ACTO SuperAgents, our field sales teams get instant access to critical information-from disease state science to compliance policies-without searching across systems," said Lisa Dreher, Director, National Sales Training, Currax Pharmaceuticals. "What once took hours now takes seconds, keeping reps focused in the field. We've accelerated time to field readiness, improved productivity and retention, and boosted confidence in HCP interactions. The feedback from our pilot was immediate-teams called it a game-changer before full rollout."

The example highlights one of the commercial arguments behind the launch. Field teams in pharmaceuticals often work in regulated settings where they need rapid access to approved content, scientific background and company policy, while also documenting actions and staying within compliance boundaries. Suppliers have increasingly tried to use AI to address those tasks, but buyers have often demanded stronger oversight and a clearer fit with specific roles.

ACTO says its platform already serves pharmaceutical, biotech and medical technology companies, and cites compliance credentials including FDA 21 CFR Part 11 validation and SOC 2 Type II certification. It also says it works with 14 of the top 50 pharmaceutical companies.

The launch reflects a wider push by technology suppliers to move beyond narrow AI assistants to software that can coordinate actions across several systems. In Life Sciences, that shift is likely to be judged not only on speed and ease of use, but also on whether companies can show that outputs are governed, traceable and suitable for highly regulated commercial and medical environments.

According to Dreher, Currax's pilot results included faster access to information, shorter preparation time and stronger confidence in interactions with healthcare professionals.